David Segarra

David, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring ApTOLL to the clinic. Previously, he was the co-founder and CEO of Aptus Biotech, an aptamer platform focused on therapeutic and diagnostic applications. AptaTargets is a spinout from Aptus Biotech. David co-founded and was General Manager of Igen, where he led the research, development, and marketing of genetic and epigenetic kits for clinical use. David has been an innovation strategy advisor for various medical institutions, an associate consultant at the international management consulting firm Arthur D. Little, and a project manager at Acciona (global energy & infrastructure firm). David holds an MBA from the IESE Business School and the University of California Berkeley, a specialty program in Business Biotechnology and an MSc. in Engineering from Barcelona Tech (UPC).